分化型甲状腺癌骨转移:放射性碘治疗肿瘤反应的异质性与总生存
这项在两家三级转诊中心开展的回顾性研究纳入1989至2015年间178例分化型甲状腺癌骨转移患者,评估总生存及完全骨转移缓解的预测因素。骨转移诊断后中位总生存为57个月,T4分期、骨转移灶18FDG摄取和RAI难治状态显著降低总生存;145例非RAI难治患者中46例(31.7%)经RAI达完全骨转移缓解,无骨外远处转移和无18FDG摄取为预测因素。
要点
- 骨转移诊断后中位总生存57个月(IQR 24–93)。
- T4分期、骨转移灶18FDG摄取和RAI难治状态与总生存显著降低相关。
- 145例非RAI难治患者中31.7%经RAI达完全骨转移缓解,无骨外远处转移和无18FDG摄取为预测因素。
核心结论
- 近三分之一RAI摄取的DTC骨转移患者经RAI单用或联合骨转移灶局部治疗可达完全骨转移缓解。
- 骨转移灶存在18FDG摄取与完全骨转移缓解缺失及总生存差相关。
- 怀疑骨转移时应行18FDG PET-CT。
研究设计与样本
- 回顾性研究,纳入1989至2015年间两家三级转诊中心连续收治的178例分化型甲状腺癌骨转移患者。
- 总生存分析在全队列进行;完全骨转移缓解分析仅纳入骨转移诊断时非RAI难治的145例患者。
主要发现
- 骨转移诊断后中位总生存为57个月(IQR 24–93)。
- 多因素分析中,T4分期、骨转移灶18FDG摄取和RAI难治状态与总生存显著降低相关。
- 145例非RAI难治患者中46例(31.7%)经RAI达完全骨转移缓解,其中32例(18%)单用RAI、14例联合骨转移灶局部治疗。
- 无骨外远处转移和无骨转移灶18FDG摄取为完全骨转移缓解的预测因素。
临床怎么用
- 怀疑骨转移时应行18FDG PET-CT。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bone metastases (BM) from differentiated thyroid carcinoma (DTC) impact negatively the quality of life and the life expectancy of patients. The aim of the study was (a) to evaluate the overall survival (OS) and prognostic factors of OS and (b) to assess predictive factors of complete BM response (C-BM-R) using radioiodine treatment (RAI) either alone or in association with focal treatment modalities. METHODS: A total of 178 consecutive DTC patients harbouring BM, treated between 1989 and 2015, were enrolled in this retrospective study conducted in two tertiary referral centers. OS analysis was performed for the whole cohort, and only the 145 considered non-RAI refractory patients at BM diagnosis were evaluated for C-BM-R following RAI. RESULTS: The median OS from BM diagnosis was 57 months (IQR: 24-93). In multivariate analysis, OS was significantly reduced in the case of T4 stage, 18FDG uptake by the BM and RAI refractory status. Among the 145 DTC considered non-RAI refractory patients at BM diagnosis, 46 patients (31.7%) achieved a C-BM-R following RAI treatment, either alone in 32 (18%) patients or in association with focal BM treatment modalities in 14. The absence of extra-skeletal distant metastasis and of 18FDG uptake in BM were predictive for C-BM-R. CONCLUSIONS: In nearly one-third of DTC patients with RAI avid BM, RAI alone or in combination with BM focal treatment can induce C-BM-R. The presence of 18FDG uptake in BM is associated with an absence of C-BM-R and with a poor OS. 18FDG PET-CT should be performed when BM is suspected.
引用
- Jannin A, Lamartina L, Moutarde C, et al. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival. Eur J Nucl Med Mol Imaging. 2022. PMID: 35149914. doi:10.1007/s00259-022-05697-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。